Home » Newsletters » BioWorld Science

BioWorld Science

March 25, 2013

View Archived Issues

A novel potential therapy for the treatment of stress-related autoimmune skin disease

Phase III trial of arbaclofen placarbil ongoing in patients with MS-related spasticity

BreastPRS as a new prognostic panel for breast cancer

GGF2 well tolerated in patients with HF at doses up to 0.75 mg/kg

Phase I trial of PD vaccine candidate PD-01A under way

Teriparatide as the first anabolic therapy for osteogenesis imperfecta

Amakem presents novel ROCK inhibitors

Bayer presents new agents for cardiovascular disorders

Anacor Pharmaceuticals reports results from phase II AN-2728 study

Cancer research institutions collaborate with Janssen to discover multiple myeloma drug

Astellas enters agreements to research new anti-dengue virus drugs

Blueprint Medicines enters oncology collaboration

ChromoTek licenses Chromobody Technology to Bayer

Guerbet announces FDA approval for Dotarem

NDA submitted for brentuximab vedotin in Japan

Updated results from ALSYMPCA trial show survival benefit

GlaxoSmithKline designs new RORgamma modulators

Novel antifungal agents presented by Toyama Chemical and Taisho

Santhera Pharmaceuticals withdraws MAA for Raxone

Metabolex patents new GPBA receptor agonists

CHMP issues positive opinion on HyQvia

Stribild gets positive opinion in Europe

FDA approves AdreView to evaluate cardiac risk in heart failure patients

Cerulean's phase IIb study of CRLX-101 in NSCLC does not meet endpoint

European CHMP recommends approval of Aubagio for relapsing-remitting MS

EMA committee recommends approval of ponatinib for two cancer indications

CHMP recommends European approval of Biogen Idec's Tecfidera

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...